NASDAQ
1.95USD
-0.03 (-1.52%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
692.7M
P/E
—
EPS
—
Beta
1.26
52W range
1.9-4.27
Day range
1.93–1.99
Open
1.99
Prev close
1.98
Volume
66.6K
Avg volume
87.9K
Dividend
0.57
IPO
2004-02-05
https://www.prnewswire.com/news-releases/evotec-and-odyssey-therapeutics-enter-ai-enabled-rd-collaboration-in-autoimmune-and-inflammatory-diseases-302844665.html · 8/6/2026+0.60
https://seekingalpha.com/article/4923273-evolution-the-market-is-overly-focused-on-asia · 7/19/2026+0.10
https://www.prnewswire.com/news-releases/ad-hoc-evotec-announces-preliminary-second-quarter-and-first-half-2026-results-and-updates-full-year-2026-outlook-302824155.html · 7/13/2026-0.80
https://seekingalpha.com/article/4919665-evolution-petroleum-solid-recent-production-and-cost-performance · 7/3/2026+0.10
https://www.prnewswire.com/news-releases/just--evotec-biologics-launches-jtrain-to-deliver-turnkey-continuous-manufacturing-for-biologics-302814150.html · 6/30/2026
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/evotec-appoints-rui-wang-as-head-of-global-in-silico-and-ai-1172707 · 6/2/2026+0.60
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/evotec-announces-nomination-of-first-preclinical-development-candidat-1163408 · 5/4/2026+1.00
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/evotec-receives-grants-to-advance-tuberculosis-treatment-1162809 · 4/30/2026+0.80
https://seekingalpha.com/article/4883658-evolution-ab-looking-for-upside · 3/18/2026+0.20
https://seekingalpha.com/article/4857755-3-lessons-i-learned-in-2025-that-cost-me-dearly · 1/7/2026-0.40
https://www.globenewswire.com/news-release/2025/10/25/3174183/0/en/No-KYC-Casinos-2025-Rakebit-Rated-as-the-Leading-No-Verification-Online-Casino.html · 10/25/2025+0.20
https://seekingalpha.com/article/4833078-evolution-ab-im-not-giving-up-yet-but-my-patience-is-running-out · 10/24/2025-0.40
Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
